Co-Micronized Palmitoylethanolamide and Rutin Associated With Hydroxytyrosol Recover Diabesity-Induced Hepatic...

Area of Science:

• Metabolic disorders
• Hepatology
• Nutraceuticals

Background:

• Metabolic dysfunction-associated fatty liver disease (MAFLD) and diabesity are linked by glucose and lipid dysregulation.
• Effective treatment may require multi-component natural products due to complex metabolic features.

Purpose of the Study:

• To assess the efficacy of NORM3, a formulation of palmitoylethanolamide-rutin (PEA-Rut) and hydroxytyrosol (HT), against hepatic damage and metabolic alterations in a mouse model of diet-induced diabesity.

Main Methods:

• High-fat diet (HFD)-induced diabesity mouse model.
• Evaluation of body weight, fat mass, glucose/lipid metabolism (tolerance tests, Western blot, qPCR).
• Histological analysis of liver tissue, assessment of oxidative stress markers and antioxidant enzyme activity.
• In vitro studies on HepG2 cells.

Main Results:

• NORM3 reduced body weight and fat mass in obese mice.
• Improved insulin sensitivity, glucose metabolism, and normalized hepatic glucose production.
• Limited hepatic steatosis and inflammation, counteracted lipid dysfunctions by activating AMPK and regulating CPT1 expression.
• Demonstrated hepatic antioxidant activity by reducing ROS and increasing detoxifying factors.
• In vitro tests confirmed synergistic protective effects of PEA-Rut and HT.

Conclusions:

• NORM3 shows significant benefits in managing hepatic damage and metabolic dysregulation associated with diabesity.
• The phytotherapeutic combination NORM3 holds potential for innovative treatment strategies against MAFLD and diabesity.